The coagulation of Limulus amebocyte lysate (LAL) can be activated through two pathways, one initiated by endotoxin and the other by ,-glucans. The two pathways join at the step of activation of the proclotting enzyme.
Limulus amebocyte lysate (LAL) is known to contain a coagulation system that can be activated by a minute amount of bacterial endotoxin (lipopolysaccharide [LPS] ). The coagulation cascade consists of three proenzymes (factor C, factor B, and proclotting enzyme) and one clottable protein (coagulogen) (7, 14) . LPS activates factor C, which then activates factor B, which in turn converts proclotting enzyme to clotting enzyme. Clotting enzyme cleaves coagulogen to yield an insoluble coagulin gel. The formation of gel clot and measurement of clotting enzyme activity by means of a synthetic chromogenic substrate constitute, respectively, the bases of the gel clot and chromogenic LAL assays for the detection of endotoxins (8, 15) . We have recently developed sensitive endotoxin assays based on the immunochemical detection of Limulus coagulogen or its cleaved fragment, peptide C, with detection limits as low as 0.001 endotoxin unit (EU) per ml (2, 24, 25) .
Because of its extreme sensitivity to endotoxins, the LAL test has been considered a promising means of detecting endotoxin in clinical settings (9) . However, its specificity for endotoxin appears to be compromised by certain ,B-glucans, originating from fungi (5, 6, 10) or hemodialysis membranes (3, 23) , which are also LAL reactive, although these glucans are at least 1,000-fold less active than endotoxin. Fortunately, the activation of LAL by 3-glucan occurs through an initiating factor different from that for endotoxin, namely, factor G (16) . Separation of the two pathways by fractionation and reconstitution of the relevant factors has been reported recently (12, 19) . Addition of curdlan, a carboxymethylated 3-glucan, to LAL at high concentrations (>1 mg/ml) has also been shown to block the ,B-glucan pathway (11) . Another (25) .
Polymyxin B. Polymyxin B sulfate was purchased from Calbiochem, La Jolla, Calif. The endotoxin and ,-glucan-like activities found in polymyxin B were removed by adsorption with activated charcoal (Merck, Darmstadt, Germany); 0.1 g was mixed with 10 ml of polymyxin B solution (20 mg/ml) at 37°C for 1 h, and this was followed by centrifugation to remove the charcoal.
MAb against factor C. Partially purified factor C was obtained from TAL by dextran sulfate-Sepharose CL-6B chromatography as described by Nakamura et al. (17) and was further purified by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) carried out with a 12% gel, essentially as described by Laemmli (13) . The band at 120 kDa was cut out and eluted with an electroelutor (Bio-Rad Laboratories, Richmond, Calif.). Purified factor C was adsorbed to aluminium hydroxide suspension (2 mg/ml in normal saline) and injected intraperitoneally (0.5 ml, containing 25 ,ug of factor C, per mouse) into five female CF1 x BALB/c mice. Booster doses were given at 2-week intervals, and animals were test bled 10 days after each boost. When high antibody titers were found by ELISA in factor C-coated microtiter plates, spleen cells were fused by a standard procedure (4) with myeloma cells from line X63/Ag8.6.5.3. Selected monoclonal antibodies (MAbs) against factor C were purified from hybridoma supernatants by affinity chromatography on protein A-Sepharose CL-4B columns (Pharmacia, Uppsala, Sweden). One of the MAbs (MAb-B2) was found to react with both Tachypleus factor C and Limulus factor C, since it recognized the 120-kDa band of the partially purified factor C preparations from both LAL and TAL in SDS-PAGE immunoblotting (unpublished observation), and was chosen for use in the present study. The endotoxin contamination of preparations containing 1 mg of MAb-B2 per ml was about 100 ng/ml and was removed by Triton X-1 14 extraction (1).
Preparation and pretreatment of plasma. Blood from human donors was drawn into pyrogen-free glass tubes containing pyrogen-free heparin (final concentration, 4 IU/ml). Plasma was separated by centrifugation at 500 x g for 15 min. Perchloric acid (PCA) precipitation of plasma to remove factors that interfere with LAL was carried out essentially as described by Obayashi (18) but with one minor modification: the neutralized supernatant was further diluted twofold in the LAL reagent water.
Limulus peptide C ELISA. Unless otherwise stated, the Limulus peptide C ELISA was performed as previously described (25) . When MAb-B2 was used as a blocking agent, stock solution (1 mg/ml) was added to diluted LAL and incubated at 4°C for 20 min before the ELISA was performed. When dimethyl sulfoxide (DMSO) and polymyxin B were used as blocking agents, the ordinary LAL buffer was replaced by buffer containing 20% (vol/vol) DMSO, 100 ,ug of polymyxin B per ml, 60 mM MgCI2, and 100 mM Tris-HCl, pH 8. 
RESULTS
Differential blocking of the endotoxin-activated LAL pathway. MAb-B2 is a murine MAb raised against factor C from TAL and was found to cross-react with factor C from LAL (see Materials and Methods) . Figure 1 shows the effect of MAb-B2 on the reactivity of LAL to LPS (from E. coli O111:B4) and to curdlan. LAL (from ACC) became almost unreactive to LPS in the presence of MAb-B2 at 10 ,ug/ml, while the reactivity of LAL to curdlan was unaltered. The same effect was also observed with other LPS preparations, as shown in Table 1 . Figure 2 shows the dose-dependent inhibition of the endotoxin-activated pathway of LAL by MAb-B2. When the concentration of the antibody in LAL was at or above 10 ,ug/ml, the reactivity of LAL to LPS was almost totally inhibited. No further inhibition was observed when the MAb-B2 concentration was increased above 20 ,ug/ml. The residual LAL reactivity of LPS at concentrations of >100 ,ug/ml was presumed to be due to the contamination of the LPS preparations with 3-glucan-like substances, since it could not be abolished even by treatment with 0.2 N NaOH at 60°C for 24 h. The concentration of MAb-B2 in LAL was 10 Kg/ml. OD490-650, optical density at 490 nm corrected by optical density at 650 nm. Figure 3 shows the effect of the combined use of 20% DMSO and polymyxin B (100 ,ug/ml) on the reactivity of LAL to LPS (from E. coli 011 1:B4). The reaction of LAL with LPS was inhibited by a factor of more than 105 (increasing the detection limit from 2.5 pg/ml to 1 jLg/ml), but the reactivity of LAL to curdlan was not significantly altered. The inhibitory effect of DMSO and polymyxin B on the reactivity of LAL to other LPS preparations was variable, ranging from a factor of 104 to 106', as shown in Table 1 .
Differential blocking of the j-glucan-activated LAL pathway. Figure 4 shows the reaction curves of LAL with LPS, laminarin, and curdlan and the effects of laminarin and curdlan on the 3-glucan-activated pathway. The concentration ranges in which laminarin and curdlan reacted with LAL were from 0.05 ng/ml to 1 .ig/ml and from 0.1 ng/ml to 500 Fg/ml, respectively. Addition of laminarin at 5 jig/ml or curdlan at I mg/ml to LAL totally blocked the ,B-glucan-activated pathway without compromising the reactivity of LAL to LPS.
The reactions of TAL with LPS and curdlan were found to be similar to those of LAL, but TAL did not react with laminarin at any concentration from 1 pg/ml to 1 mg/ml (25 10 ,ug/ml. f D-P, DMSO-polymyxin B. The LAL buffer containing 20% DMSO, 100 ,ug of polymyxin B 100 per ml, 60 mM MgCl2, and 100 mM Tris-HCI (pH 8) was used to dilute the LAL in the Limulus peptide C ELISA.
,ug/ml was sufficient to block the f-glucan pathway activated by curdlan.
Standard curves of Limulus peptide C ELISAs specific for LPS or 0-glucan. Figure 5 shows a linear relationship (on a double logarithmic plot) of the LAL reaction with LPS when laminarin (5 ,ug/ml) was added to LAL to block the P-glucanactivated pathway and also shows a linear relationship of the reaction with ,B-glucan when either MAb-B2 or DMSO and polymyxin B were added to block the LPS-activated pathway. The detection limit for LPS in the LPS-specific ELISA was 0.005 EU/ml, while the detection limit for curdlan or laminarin in the ,B-glucan-specific ELISA was about 50 pg/ml. Curdlan was found to be unstable in solution at concentrations of >1 mg/ml, since it autopolymerized to form an insoluble gel after storage at 4°C for 3 months. Laminarin was observed to be stable at 1 mg/ml in 50 mM NaOH at 4°C for at least 1 year.
Comparison of different formulations of LAL and TAL for the determination of LPS and 13-glucan in specimens. As shown in Table 2 , the conventional LAL or TAL preparations, which react with both LPS and ,B-glucan, gave much more variable results (the coefficient of variation was more than double) for specimens that contained primarily 3-glucans (samples 4 and 5) than for specimens that contained both LPS and ,B-glucans (samples 1, 2, and 3). The LAL or TAL made specific for LPS by the addition of laminarin (5 ,ug/ml) reacted little with the specimens containing primarily 3-glucans and produced less variation than the conventional preparations.
The LAL made specific for ,3-glucan by the addition of MAb-B2 gave results comparable to those obtained by the addition of DMSO and polymyxin B. PCA-treated normal human plasma exhibited some ,B-glucan-like activity, but no endotoxin activity, when LAL preparations were used and diluted fourfold. DISCUSSION The LAL test is widely used as a sensitive assay for endotoxin. It is now known that the coagulation of LAL can be induced not only by LPS but also by certain 3-glucans, which act through different initiating factors. LPS activates factor C and 3-glucan activates factor G, although the latter has not been fully characterized (14) . MAb-B2, used in this study, is a MAb raised against Tachypleus factor C but is found to react with and inhibit both Limulus factor C and Tachypleus factor C. This indicates the close similarity of the factors C from these species, which have also been demonstrated to have the same molecular size and functions (22) . While the exact mechanism of MAb-B2 inhibition of the activation of factor C by LPS is not clear, it is possible that the binding of factor C to MAb-B2 prevents its binding to LPS and consequent activation through an allosteric effect or one of steric hindrance by MAb-B2, as suggested by the fact that premixing of the antibody with LAL or TAL at 4°C for about 15 to 30 min is required to ensure effective blocking of the LPS-activated pathway.
The use of laminarin to block the 3-glucan-activated pathway has advantages over the use of curdlan in that laminarin is stable in solution and is effective at a concentration at least 100-fold lower than that of curdlan. Commercial curdlan and laminarin, in solutions of 5 mg/ml, contain about 1 ng of endotoxin per ml. The contaminating endotoxin can be totally destroyed by heating to 50 to 60°C in 0.2 N NaOH for about 6 h, without affecting the LAL reactivities of curdlan and laminarin. However, the curdlan solutions subjected to this treatment seem to be more susceptible to gelling, probably because of autopolymerization, than untreated solutions (gelling within 3 months after treatment versus 1 year). It is desirable to use as differential blocking agents those ,B-glucans that have no reactivity with LAL at any concentration and that can produce total inhibition of the 3-glucan-activated pathway without affecting the LPS-activated pathway. Tanaka et al. (21) have recently reported the inhibition of high-molecular-weight (1-3)-p-D-glucan-dependent activation of Limulus coagulation factor G by laminaran oligosaccharides and curdlan degradation products.
Inhibition of the LPS-activated pathway by the combined use of DMSO and polymyxin B is based on the LPS-neutralizing effect of polymyxin B and the inhibitory effect of DMSO on factor C (unpublished observation). The inhibition of the LAL reactivity of LPS by polymyxin B alone at 100 ,ug/ml or by 20% DMSO alone is limited, increasing the detection limit of the assay to about 10 ng of LPS per ml, but combining the two reagents produces a synergistic effect.
Greater variations occur among different LAL and TAL preparations in quantifying ,-glucans than in quantifying LPS, and this probably stems from the different reactivities of these preparations to curdlan, which is used as a control standard for 3-glucan, and to other naturally occurring 3-glucans. For example, the TAL prepared in our laboratory and the LAL from WB used in this study are amebocyte lysates that have not been subjected to chloroform treatment, and these preparations have been found to react with curdlan but not with laminarin, while the LAL from ACC, which is a chloroformtreated preparation, reacts with curdlan and laminarin with almost equal sensitivities (25 
